Aldosterone Receptor Inhibitors
2 drugsAbout Aldosterone Receptor
The Aldosterone Receptor, or mineralocorticoid receptor (MR), regulates sodium and potassium balance. As a ligand-activated transcription factor, aldosterone binding triggers gene expression changes, crucial for blood volume and pressure maintenance.
Given its role in blood pressure, the Aldosterone Receptor is a cardiovascular drug target. Currently, there is no genetic evidence data available linking the Aldosterone Receptor to specific diseases.
The Aldosterone Receptor is targeted by two FDA-approved small molecule drugs: ALDACTONE (Pfizer) and CAROSPIR (CMP DEV LLC). These drugs are used in cardiovascular therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bioavailability Heathy Volunteers with only 1 trials.
Top Aldosterone Receptor Drugs
The competitive landscape includes Pfizer and CMP DEV LLC, each with approved drugs.
The presence of established players suggests high barriers to entry for new competitors.
Aldosterone Receptor Drug Modality Landscape
Modalities
Routes of Administration
Aldosterone Receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities could provide a competitive advantage in this space.
Aldosterone Receptor Clinical Trials 116 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 13 | 4 | 4 | 76% |
| Phase 2 | 40 | 25 | 4 | 10 | 86% |
| Phase 3 | 22 | 17 | 1 | 4 | 94% |
| Phase 4 | 33 | 16 | 10 | 6 | 62% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Aldosterone Receptor Drug Approval Timeline (1960 - 2017)
The first drug was approved in 1960, with the most recent in 2017, spanning 58 years.
The long approval span suggests a mature market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 89 clinical trials targeting Aldosterone Receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities